JP2018506554A - ナノ粒子組成物 - Google Patents

ナノ粒子組成物 Download PDF

Info

Publication number
JP2018506554A
JP2018506554A JP2017544867A JP2017544867A JP2018506554A JP 2018506554 A JP2018506554 A JP 2018506554A JP 2017544867 A JP2017544867 A JP 2017544867A JP 2017544867 A JP2017544867 A JP 2017544867A JP 2018506554 A JP2018506554 A JP 2018506554A
Authority
JP
Japan
Prior art keywords
composition
oil
particles
water
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017544867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506554A5 (enExample
Inventor
ボマガニ、マドゥスダン
ボウミック，スバス・バララム
ケイン，パラシャント
デュビー，バイブハフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of JP2018506554A publication Critical patent/JP2018506554A/ja
Publication of JP2018506554A5 publication Critical patent/JP2018506554A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017544867A 2015-02-25 2016-02-25 ナノ粒子組成物 Ceased JP2018506554A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN623MU2015 2015-02-25
IN623/MUM/2015 2015-02-25
PCT/IN2016/050068 WO2016135754A1 (en) 2015-02-25 2016-02-25 Nanoparticulate composition

Publications (2)

Publication Number Publication Date
JP2018506554A true JP2018506554A (ja) 2018-03-08
JP2018506554A5 JP2018506554A5 (enExample) 2019-05-16

Family

ID=56789380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017544867A Ceased JP2018506554A (ja) 2015-02-25 2016-02-25 ナノ粒子組成物

Country Status (6)

Country Link
US (1) US10512608B2 (enExample)
EP (1) EP3261619A4 (enExample)
JP (1) JP2018506554A (enExample)
AU (1) AU2016224863A1 (enExample)
CA (1) CA2977612A1 (enExample)
WO (1) WO2016135754A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550363A (ja) * 2020-11-17 2023-12-01 アーキュティス・バイオセラピューティクス・インコーポレーテッド 深部皮膚薬物送達のための組成物および方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518642A (ja) * 2000-12-06 2004-06-24 ファルマシア・コーポレーション ラボラトリースケールの微粉砕化プロセス
JP2005536512A (ja) * 2002-07-16 2005-12-02 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
US20080188446A1 (en) * 2007-02-02 2008-08-07 Warner Chilcott Company Inc. Tetracycline compositions for topical administration
US20130064777A1 (en) * 2009-10-02 2013-03-14 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels their uses
WO2014083311A1 (en) * 2012-11-27 2014-06-05 Hovione International Ltd Tetracycline topical formulations, preparation and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20160158261A1 (en) 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
GB0403702D0 (en) 2004-02-19 2004-03-24 Boots Co Plc Skincare compositions
US8920821B2 (en) * 2006-04-14 2014-12-30 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
US20080188445A1 (en) 2007-02-02 2008-08-07 Warner Chilcott Company Inc. Tetracycline compositions for topical administration
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
US8784852B2 (en) 2009-02-27 2014-07-22 Audrey Kunin Topical skin care composition
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
MX354137B (es) 2011-01-19 2018-02-14 Laboratory Skin Care Inc Composiciones topicas de minociclina y metodos de uso de la misma.
WO2015075640A1 (en) 2013-11-20 2015-05-28 Lupin Limited Stable pharmaceutical formulation(s) of tetracycline antibiotic
MY188541A (en) 2014-01-29 2021-12-21 Vyome Therapeutics Ltd Besifloxacin for the treatment of resistant acne

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518642A (ja) * 2000-12-06 2004-06-24 ファルマシア・コーポレーション ラボラトリースケールの微粉砕化プロセス
JP2005536512A (ja) * 2002-07-16 2005-12-02 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
US20080188446A1 (en) * 2007-02-02 2008-08-07 Warner Chilcott Company Inc. Tetracycline compositions for topical administration
US20130064777A1 (en) * 2009-10-02 2013-03-14 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels their uses
WO2014083311A1 (en) * 2012-11-27 2014-06-05 Hovione International Ltd Tetracycline topical formulations, preparation and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 7, JPN6019045363, 2012, pages 221 - 234, ISSN: 0004158308 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550363A (ja) * 2020-11-17 2023-12-01 アーキュティス・バイオセラピューティクス・インコーポレーテッド 深部皮膚薬物送達のための組成物および方法
JP7609994B2 (ja) 2020-11-17 2025-01-07 アーキュティス・バイオセラピューティクス・インコーポレーテッド 深部皮膚薬物送達のための組成物および方法

Also Published As

Publication number Publication date
WO2016135754A1 (en) 2016-09-01
US20180036243A1 (en) 2018-02-08
EP3261619A4 (en) 2018-10-24
CA2977612A1 (en) 2016-09-01
AU2016224863A1 (en) 2017-10-12
EP3261619A1 (en) 2018-01-03
US10512608B2 (en) 2019-12-24

Similar Documents

Publication Publication Date Title
JP2018506554A (ja) ナノ粒子組成物
ES2382890T3 (es) DMS (derma membrane structure) en cremas de espuma.
ES2972843T3 (es) Composiciones farmacéuticas de roflumilast en mezclas acuosas de disolventes farmacéuticamente aceptables miscibles en agua
US20190307656A1 (en) Foam containing unique oil globules
US20120064135A1 (en) Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
ES2692820T3 (es) Producto cosmético de filtro solar
US20170246111A1 (en) Active-loaded particulate materials for topical administration
JPH072644A (ja) 好ましくは微小球体の形をしたガレヌス製剤マトリツクス
CN105934239A (zh) 优选包含亲脂性活性剂的脂质微胶囊和包含它的组合物，它们的制备方法和它们在皮肤病学和化妆品中的用途
CA3023725A1 (en) Methods of producing hydrated flavonoids and use thereof in the preparation of topical compositions
JP2003533491A (ja) 薬学的及び／又は美容的組成物
JP6460988B2 (ja) 使用時泡状を呈する外用組成物
US20160184228A1 (en) UNILAMELLAR NIOSOMES HAVING HIGH Kow PHARMACOLOGICAL COMPOUNDS SOLVATED THEREIN AND A METHOD FOR THE PREPARATION THEREOF
WO2005000287A1 (ja) 水虫治療用外用剤
JP5816194B2 (ja) カルシポトリオール一水和物ナノクリスタル
CN112566623A (zh) 局部用油质组合物
IL294239A (en) Topical composition comprising tofacitinib and fingolimod
Azhar et al. Review of nanoemulgel for treatment of fungal infections
US20250073251A1 (en) Compositions and methods and uses thereof
JP2018506552A (ja) ナノ粒子局所組成物を調製する方法
JP6462260B2 (ja) 泡状外用医薬組成物
KR20220056669A (ko) 세라마이드를 고함량으로 포함하는 무수 젤 및 이를 포함하는 화장료 조성물
JP4959991B2 (ja) トラニラストまたはその薬理学的に許容される塩を含有する懸濁性医薬組成物
KR20210047989A (ko) 이데베논 및 비사보롤을 포함하는 나노 리포좀
KR20250170060A (ko) 가압 나노에멀젼

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190405

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191111

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191126

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20200407